CR10846A - Formas cristalinas glyt1 - Google Patents
Formas cristalinas glyt1Info
- Publication number
- CR10846A CR10846A CR10846A CR10846A CR10846A CR 10846 A CR10846 A CR 10846A CR 10846 A CR10846 A CR 10846A CR 10846 A CR10846 A CR 10846A CR 10846 A CR10846 A CR 10846A
- Authority
- CR
- Costa Rica
- Prior art keywords
- glyt1
- glass forms
- trifluor
- methanone
- fluor
- Prior art date
Links
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 title 1
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 title 1
- 239000011521 glass Substances 0.000 title 1
- -1 3-fluor-5-trifluoromethyl-pyridin-2-yl Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127269 | 2006-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10846A true CR10846A (es) | 2009-08-12 |
Family
ID=38988312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10846A CR10846A (es) | 2006-12-28 | 2009-06-08 | Formas cristalinas glyt1 |
Country Status (33)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0720829B8 (pt) | 2006-12-28 | 2021-05-25 | Hoffmann La Roche | formas cristalinas de glyt1, seu método de preparação, seu uso e composição farmacêutica que as compreende |
| WO2010099323A1 (en) | 2009-02-26 | 2010-09-02 | Thar Pharmaceuticals, Inc. | Crystalization of pharmaceutical compounds |
| KR101196354B1 (ko) * | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
| US9328101B2 (en) * | 2012-05-25 | 2016-05-03 | Basf Se | Crystalline form B of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[B][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione |
| US8927412B1 (en) * | 2013-08-01 | 2015-01-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-chip package and method of formation |
| MX354615B (es) * | 2013-10-02 | 2018-03-08 | Centro De Investig Y De Estudios Avanzados Del I P N | Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus. |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
| WO2022014395A1 (ja) * | 2020-07-13 | 2022-01-20 | 日本碍子株式会社 | 精製方法 |
| CN117979967A (zh) * | 2021-05-14 | 2024-05-03 | 迪斯克医药公司 | 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
| EP4347023A4 (en) * | 2021-05-27 | 2025-04-16 | Disc Medicine, Inc. | Method for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| NZ544820A (en) * | 2003-08-11 | 2009-02-28 | Hoffmann La Roche | Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors |
| BRPI0720829B8 (pt) | 2006-12-28 | 2021-05-25 | Hoffmann La Roche | formas cristalinas de glyt1, seu método de preparação, seu uso e composição farmacêutica que as compreende |
-
2007
- 2007-12-18 BR BRPI0720829A patent/BRPI0720829B8/pt active IP Right Grant
- 2007-12-18 JP JP2009543441A patent/JP4799666B2/ja active Active
- 2007-12-18 ES ES07857734.3T patent/ES2535040T3/es active Active
- 2007-12-18 KR KR1020097015643A patent/KR101130146B1/ko active Active
- 2007-12-18 RS RS20150229A patent/RS53910B1/sr unknown
- 2007-12-18 UA UAA200907731A patent/UA100232C2/uk unknown
- 2007-12-18 PT PT78577343T patent/PT2114405E/pt unknown
- 2007-12-18 DK DK07857734T patent/DK2114405T3/en active
- 2007-12-18 EP EP07857734.3A patent/EP2114405B1/en active Active
- 2007-12-18 MX MX2009006859A patent/MX2009006859A/es active IP Right Grant
- 2007-12-18 CA CA002673667A patent/CA2673667A1/en not_active Abandoned
- 2007-12-18 MY MYPI20092584A patent/MY188367A/en unknown
- 2007-12-18 WO PCT/EP2007/064104 patent/WO2008080821A1/en not_active Ceased
- 2007-12-18 HU HUE07857734A patent/HUE025032T2/en unknown
- 2007-12-18 RU RU2009124113/04A patent/RU2463295C2/ru active
- 2007-12-18 CN CNA2007800479512A patent/CN101573114A/zh active Pending
- 2007-12-18 SI SI200731644T patent/SI2114405T1/sl unknown
- 2007-12-18 PL PL07857734T patent/PL2114405T3/pl unknown
- 2007-12-18 AU AU2007341356A patent/AU2007341356B2/en active Active
- 2007-12-18 NZ NZ577502A patent/NZ577502A/en unknown
- 2007-12-18 HR HRP20150573TT patent/HRP20150573T1/hr unknown
- 2007-12-19 US US12/002,997 patent/US20080214561A1/en not_active Abandoned
- 2007-12-25 TW TW096150002A patent/TWI388552B/zh active
- 2007-12-27 CL CL200703830A patent/CL2007003830A1/es unknown
- 2007-12-27 AR ARP070105913A patent/AR064545A1/es not_active Application Discontinuation
-
2008
- 2008-01-02 PE PE2008000055A patent/PE20081556A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 CR CR10846A patent/CR10846A/es unknown
- 2009-06-11 CO CO09061117A patent/CO6190613A2/es not_active Application Discontinuation
- 2009-06-19 NO NO20092358A patent/NO342150B1/no unknown
- 2009-06-24 ZA ZA200904423A patent/ZA200904423B/xx unknown
- 2009-06-26 EC EC2009009471A patent/ECSP099471A/es unknown
- 2009-06-29 MA MA32049A patent/MA31029B1/fr unknown
-
2010
- 2010-07-22 US US12/841,195 patent/US8039473B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 US US13/188,486 patent/US20110295007A1/en not_active Abandoned
-
2012
- 2012-06-13 US US13/495,093 patent/US20120309969A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/798,358 patent/US20130197225A1/en not_active Abandoned
-
2015
- 2015-05-20 CY CY20151100451T patent/CY1116350T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30320A1 (es) | Formas polimorficas de 1-((4-metil-quinazolin-2-il)metil)--3-metil-7-(2-butin-1-il)-8-(3-(r)-amino-piperidin-1-il)-xantina, preparaciones, composiciones de preparacion y aplicaciones de las mismas. | |
| ECSP066376A (es) | FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN | |
| CR8249A (es) | Forma cristalina gamma del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que lo contienen | |
| WO2008002683A3 (en) | Polymorphous forms of carvedilol phosphate | |
| UY30639A1 (es) | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones | |
| NI200600240A (es) | FORMA CRISTALINA Delta-d CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN, Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN | |
| HN2006014095A (es) | Forma cristalina ortorrombica del maleato de asenapina | |
| SV2009003285A (es) | Forma cristalina del hemihidrato de 1-(beta-d-glucopiranosil)-4-metil-3-[ 5-(4-fluorofenil)-2- tienilmetil] benceno | |
| AR078766A1 (es) | Formas solidas de n-(4-(7-azabiciclo(2.2.1) heptan-7-il)-2-( trifluorometil) fenil)-4-oxo-5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida | |
| WO2009036281A3 (en) | Bortezomib and process for producing same | |
| NO20073875L (no) | Krystallformer av 1-klor-4-(B-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzyl]-benzen, metode for fremstilling samt anvendelse for fremstilling av medikamenter | |
| NI200800294A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen. | |
| MY150542A (en) | Cmet inhibitors | |
| WO2007089768A3 (en) | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them | |
| HN2006016313A (es) | Derivados de amida sustituida y metodos de uso | |
| TN2010000131A1 (en) | Polo-like kinase inhibitors | |
| CR9569A (es) | Modificaciones cristalinas de la piraclostrobina | |
| ECSP066374A (es) | FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN | |
| CL2007003830A1 (es) | Formas cristalinas a, b, y c, forma amorfa y forma co-cristalina de [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona; metodos de preparacion; composicion farmaceutica; y | |
| WO2008116107A3 (en) | Piperazine derivatives as glucokinase activators | |
| IL206576A (en) | Bite [3– (3– {4– [3– (beta-d– glucopyranosiloxy) –5 – isopropyl– h1– pyramiding - 4-ylmethyl] –3– methylphenoxy} -propylamino) –2,2-dimethylpropynamide] monosaccharide and forms Crystals, pharmaceuticals containing them and their uses | |
| FI20070174A0 (fi) | Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt | |
| WO2007054453A3 (en) | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa | |
| MX2010008583A (es) | Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico. | |
| MX2010007784A (es) | 2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran -4-il)-propionamida cristalina. |